Dr. Jordan Plews, co-founder of ELEVAI Labs and biotechnology researcher,
stated in March 2026 that “EU and UK authorities have already taken action
against human-derived exosome cosmetics in beauty clinics”
(The Aesthetic Guide, March 2026).
Meanwhile, Japan — one year after its amended Regenerative Medicine Act took effect
on May 31, 2025 — has still not published specific regulations on exosomes.
The regulatory asymmetry between Japan, the United States, and Europe
continues to generate patient risk.
📌 Key Takeaways
- EU and UK (MHRA) authorities have begun regulatory action
against human-derived exosome cosmetics in beauty clinics,
according to expert testimony in The Aesthetic Guide (March 2026). - The U.S. FDA has stated clearly:
“Zero approvals exist for cosmetic exosome applications.
Administering unapproved biological agents to patients violates federal law.” - Japan’s amended Regenerative Medicine Act took effect May 31, 2025.
The Ministry of Health, Labour and Welfare (MHLW) indicated regulations
would be in place “by 2026” — yet as of June 2026, no specific rules have been published. - 669 clinics in Japan (2023 survey) were offering exosome treatments,
many injecting products sold as “research reagents” — not approved pharmaceuticals. - No quality, purity, or manufacturing standards are enforced for these products.
Patients who experience adverse effects may be ineligible for Japan’s drug injury relief program.
“My skin completely changed after exosome injections.”
“I felt full-body rejuvenation from an exosome IV drip.” —
Exosomes have become one of the most talked-about treatments
in Japan’s aesthetic medicine market in 2026.
But the global picture looks very different.
In the U.S.: zero approvals, federal law violation.
In Europe: regulatory action has begun.
In Japan: still a gray zone.
INDEX
What Are Exosomes? A 2026 Primer
Exosomes are microscopic vesicles (30–150 nm in diameter)
secreted by cells throughout the body.
They carry mRNA, miRNA, proteins, and growth factors,
and are involved in cell-to-cell signaling, tissue repair, and inflammation regulation —
often described as the body’s “cellular postal system.”
In aesthetic medicine, exosomes are marketed for:
・Stimulating fibroblasts to boost collagen and elastin production
・Delivering tissue-repair signals to damaged skin
・Reducing inflammation and improving skin environment
However, the idea that exosomes are a universal anti-aging solution is overstated.
Verifying product quality, purity, and actual exosome content is difficult.
As of 2026, large-scale clinical trials for cosmetic applications remain limited.
Three Regulatory Environments, Three Very Different Responses
Japan’s Market Reality: Injecting Research Reagents Into Patients
(Kyoto University group survey, published in international journal)
exempt from pharmaceutical Good Manufacturing Practice (GMP) standards
for regulating cell-secreted substances — specific rules not yet published as of June 2026
What Patients Can Do Right Now: 4 Questions to Ask
- “Can you show me the Certificate of Analysis (CoA) for this exosome product?”
If the clinic cannot provide one, product quality is not guaranteed. - “What is the origin of these exosomes — human-derived, plant-derived, or synthetic?”
Human-derived exosomes carry higher regulatory risk;
risk profiles differ significantly by source. - “If I experience side effects, am I eligible for Japan’s drug injury relief program?”
In most cases, the answer will be no —
knowing this in advance is essential to informed consent. - “Does this treatment require registration under the Regenerative Medicine Act?”
Currently it does not — but regulations may change by 2027.
Ask the clinic about their policy going forward.
NERO is not saying exosomes are dangerous.
The potential of exosomes as intercellular signaling agents is real —
and treatments conducted under proper quality controls are not inherently problematic.
What NERO is pointing to is a structural problem:
patients are being exposed to treatments
where quality and purity cannot be verified.
While Europe acts and the U.S. prohibits,
Japan alone remains in a state of “not yet regulated.”
“Gray zone” does not mean “safe.”
It means “not yet regulated.”
Know the difference before you decide.
Summary
- EU and UK (MHRA) authorities have begun regulatory action
against exosome cosmetics in beauty clinics, as reported by industry experts in March 2026. - The U.S. FDA has stated zero approvals exist and that administration constitutes a federal law violation.
The regulatory asymmetry between Japan, the U.S., and Europe
creates ongoing patient risk. - 669 clinics in Japan offer exosome treatments,
but no quality or purity standards are enforced,
and patients may be excluded from Japan’s drug injury relief program. - MHLW has indicated regulations will be in place by May 2027,
but as of June 2026, no specific rules have been published.
Patients should use the four questions above as a guide before proceeding.
Frequently Asked Questions
the immediate risk is likely low.
However, because Japan lacks a system to guarantee product quality and purity,
long-term safety remains uncertain.
If you have any concerns, contact the clinic where you received the treatment.
② a clear explanation of the product’s origin (human, plant, or synthetic);
③ reference to guidance from the Japanese Society for Regenerative Medicine or equivalent bodies.
Note that higher price does not equal higher quality.
set a target of “within two years of enactment” — meaning by May 2027.
As of June 2026, no specific regulatory content has been published.
Some form of regulatory movement is expected between 2026 and 2027.
NERO will continue to report on developments as they emerge.
Sources
The Aesthetic Guide, “Regenerative Medicine’s Polarizing Shift in Aesthetics,” March 30, 2026
(Statement by Jordan Plews, PhD, Co-founder, ELEVAI Labs) /
Ministry of Health, Labour and Welfare (MHLW), “Partial Amendment to the Act on the Safety of Regenerative Medicine,”
promulgated June 2024, effective May 31, 2025 /
MHLW Pharmaceutical Bureau, “Notice on Monitoring and Guidance Regarding Medical Use of Exosome Reagents,”
July 31, 2024 /
HifukoNEWS, “Exosome Treatments Offered at 669 Domestic Facilities,” October 2024 /
FDA, “Statement on Exosome Products,” 2025 /
IAPAM, “Exosome Therapy in Aesthetic Practice: FDA Regulations 2026,” May 2026
